Torben Jörgensen New CEO at Biotage
The life science company Biotage makes a further strategic move to integrate its acquired businesses and to optimize the product portfolio, with the intention to focus on organic growth. As a part of this process, Torben Jörgensen will succeed Jeff Bork as the CEO of the company.
For the last four years, Torben Jörgensen was the CEO of Affibody. Prior to that, he held similar positions at the Swedish biotech company Karo Bio, listed in Stockholm, and the Danish life science company DAKO, which annual turnover grew from DKK 230 million to DKK 820 million during Torben Jörgensens period as a CEO between 1990 and 1999. During this time, the global operating result rose from DKK 10 million to DKK 75 million.
Torben Jörgensen will enter his duties as CEO of Biotage in conjunction with the annual general assembly on 27 April.
Jeff Bork will continue as a board member of Biotage, with a special focus on strategic issues. During his years as a chairman and CEO of the company, Jeff Bork carried through strategic acquisitions and extensive cost reductions at Biotage, and lowered the consolidated costs in the businesses with SEK 400 million.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
